Sample Size Requirements for Multivariate Models to Predict Between-Patient Differences in Best Treatments of Major Depressive Disorder

被引:95
作者
Luedtke, Alex [1 ,2 ]
Sadikova, Ekaterina [3 ]
Kessler, Ronald C. [3 ]
机构
[1] Univ Washington, Dept Stat, B313 Padelford Hall,Northeast Stevens Way, Seattle, WA 98195 USA
[2] Fred Hutchinson Canc Res Ctr, Vaccine & Infect Dis Div, 1124 Columbia St, Seattle, WA 98104 USA
[3] Harvard Med Sch, Dept Hlth Care Policy, Boston, MA 02115 USA
关键词
depression treatment; heterogeneity of treatment effects; power analysis; prescriptive predictors; targeted minimum-loss estimation (TMLE); ANTIDEPRESSANT RESPONSE; ESTABLISHING MODERATORS; CLINICAL-TRIALS; PHARMACOGENETICS; IDENTIFICATION; BIOSIGNATURES; RATIONALE; REMISSION; ADHERENCE; INFERENCE;
D O I
10.1177/2167702618815466
中图分类号
B849 [应用心理学];
学科分类号
040203 ;
摘要
Clinical trials have documented numerous clinical features, social characteristics, and biomarkers that are "prescriptive" predictors of depression treatment response, that is, predictors of which types of treatments are best for which patients. On the basis of these results, research is actively under way to develop multivariate prescriptive prediction models to guide precision depression treatment planning. However, the sample size requirements for such models have not been analyzed. We present such an analysis here. Simulations using realistic parameter values and a state-of-the-art cross-validated targeted minimum loss-based prescription treatment response estimator show that at least 300 patients per treatment arm are needed to have adequate statistical power to detect clinically significant underlying marginal improvements in treatment response because of precision treatment selection. This is a considerably larger sample size than in most existing studies. We close with a discussion of practical study design options to address the need for larger sample sizes in future studies.
引用
收藏
页码:445 / 461
页数:17
相关论文
共 75 条
[1]   Health Care Contacts in the Year Before Suicide Death [J].
Ahmedani, Brian K. ;
Simon, Gregory E. ;
Stewart, Christine ;
Beck, Arne ;
Waitzfelder, Beth E. ;
Rossom, Rebecca ;
Lynch, Frances ;
Owen-Smith, Ashli ;
Hunkeler, Enid M. ;
Whiteside, Ursula ;
Operskalski, Belinda H. ;
Coffey, M. Justin ;
Solberg, Leif I. .
JOURNAL OF GENERAL INTERNAL MEDICINE, 2014, 29 (06) :870-877
[2]   Healthcare outcomes assessed with observational study designs compared with those assessed in randomized trials [J].
Anglemyer, Andrew ;
Horvath, Hacsi T. ;
Bero, Lisa .
COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2014, (04)
[3]  
[Anonymous], FASTER RATES POLICY
[4]   Simulation methods to estimate design power: an overview for applied research [J].
Arnold, Benjamin F. ;
Hogan, Daniel R. ;
Colford, John M., Jr. ;
Hubbard, Alan E. .
BMC MEDICAL RESEARCH METHODOLOGY, 2011, 11
[5]  
Bembom O, 2007, STAT APPL GENET MOL, V6
[6]  
Bertolote Jose Manoel, 2004, Crisis, V25, P147, DOI 10.1027/0227-5910.25.4.147
[7]   Random forests [J].
Breiman, L .
MACHINE LEARNING, 2001, 45 (01) :5-32
[8]   Vagal Nerve Stimulation for Treatment-Resistant Depression [J].
Carreno, Flavia R. ;
Frazer, Alan .
NEUROTHERAPEUTICS, 2017, 14 (03) :716-727
[9]   Inference about the expected performance of a data-driven dynamic treatment regime [J].
Chakraborty, Bibhas ;
Laber, Eric B. ;
Zhao, Ying-Qi .
CLINICAL TRIALS, 2014, 11 (04) :408-417
[10]  
Cohen ZD, 2018, ANNU REV CLIN PSYCHO, V14, P209, DOI [10.1146/annurev-clinpsy-050817-084746, 10.1146/annurev-clinpsy-050817084746]